Clinical Trial Update: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating relatlimab (anti-LAG-3) plus nivolumab (anti-PD-1) versus lomustine for recurrent glioblastoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Progressive Glioblastoma

Drugs mentioned

• Lomustine (Lomustine)
• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Status: SUSPENDED